lassa
viru
infect
elicit
distinct
chang
host
gene
express
metabol
focu
chang
host
gene
express
may
biomark
discrimin
individu
pathogen
may
help
provid
prognosi
diseas
addit
assess
mrna
chang
function
studi
also
need
discrimin
caus
diseas
mechan
host
resist
host
respons
drive
pathogenesi
like
target
prevent
therapi
host
respons
lassa
relat
arenavirus
monitor
cell
cultur
anim
model
hemorrhag
fever
lassainfect
nonhuman
primat
limit
extent
infect
human
be
describ
result
studi
discuss
potenti
target
reduc
viru
replic
mitig
diseas
test
revers
passiv
hemagglutin
inhibit
complement
fix
antibodi
detect
first
techniqu
test
lasv
diagnost
detect
antibodi
appear
late
infect
use
surveil
popul
indirect
immunofluoresc
assay
ifa
use
lf
antibodi
detect
increas
fourtim
igglasv
titer
igg
admiss
igmlasv
titer
consid
posit
howev
specif
low
popul
small
appar
risk
infect
distinguish
lasv
strain
ifa
detect
antibodi
day
onset
ill
day
faster
cytopath
effect
cpe
seen
viru
isol
elisa
develop
lasvigg
lasvigm
antigen
detect
test
improv
sensit
specif
howev
earli
detect
improv
except
use
antigen
assay
posit
day
patient
admiss
studi
show
increas
sensit
specif
combin
igm
antigen
assay
detect
rare
fast
enough
patient
initi
therapi
surviv
also
import
avoid
unnecessari
ribavirin
therapi
case
patient
suffer
diseas
molecular
method
western
blot
analysi
also
tri
detect
mainli
np
antibodi
use
techniqu
possibl
detect
igg
igm
np
acut
sampl
low
posit
predict
valu
high
neg
predict
valu
revers
transcriptionpcr
rtpcr
prove
use
lasv
detect
sensit
use
specif
primer
conserv
region
segment
posit
predict
valu
achiev
compar
ifa
test
three
sequenti
sampl
admiss
increas
posit
predict
valu
compar
ifa
later
protocol
optim
includ
realtim
pcr
assay
second
round
amplif
nest
pcr
target
sever
site
l
segment
combin
pcr
sequenc
pcr
issu
strain
variat
nucleotid
mismatch
crosscontamin
high
implement
cost
resourcepoor
countri
new
method
call
later
flow
immunoassay
enabl
npspecif
antigen
detect
serum
sampl
preclin
studi
lf
consortium
corgenix
medic
corpor
co
usa
diagnost
describ
far
detect
protein
nucleic
acid
lasv
host
respons
infect
might
also
contribut
accur
diagnosi
abil
predict
clinic
diseas
studi
rhesu
macaqu
infect
lcmv
peopl
infect
influenza
establish
pattern
virusspecif
host
respons
occur
viremia
goal
work
develop
diagnost
chip
measur
chang
host
gene
express
predict
diseas
onset
unfortun
despit
great
deal
research
invest
predict
chip
diagnost
current
avail
due
great
persontoperson
variat
diseas
suscept
immun
respons
specul
problem
human
variat
could
solv
intens
effort
classifi
peopl
transcriptom
type
exampl
character
blood
transcriptom
healthi
peopl
hierarch
cluster
profil
may
possibl
determin
whether
cluster
follow
extern
characterist
gender
age
ethnic
metabol
rate
size
among
other
let
us
imagin
cluster
allow
us
classifi
subject
five
group
sinc
biomark
chip
analysi
reli
comparison
appropri
healthi
control
healthi
person
group
serv
compar
get
sick
profil
nhp
possibl
use
preinfect
blood
healthi
control
result
consist
singl
anim
base
nhp
studi
nextgener
lasv
diagnost
would
determin
whether
suspect
lassa
case
drop
mrna
rise
mrna
chemokin
receptor
drop
rise
would
respect
express
gene
healthi
compar
sick
person
fit
profil
would
like
harbor
virul
case
lf
diseas
clinic
laboratori
diagnosi
lasv
improv
last
year
introduct
new
antibodi
nucleic
acid
detect
assay
new
technolog
shorten
time
infect
diagnosi
fail
detect
infect
incub
period
thu
import
opportun
advanc
lf
diagnost
incorpor
earli
pattern
host
respons
pathogen
detect
date
vaccin
therapi
specif
licens
lf
patient
suspect
lf
treat
base
symptom
differenti
diagnosi
support
measur
aggress
rehydr
blood
transfus
continu
monitor
use
avail
probabl
lasv
infect
high
patient
isol
ribavirin
licens
antivir
drug
report
activ
lasv
junin
junv
machupo
virus
macv
howev
util
limit
must
administr
earli
diseas
time
diagnosi
difficult
patient
treat
seven
day
onset
fever
mortal
rate
compar
individu
treat
first
day
fever
intraven
ribavirin
optim
rout
administr
costli
wide
avail
new
antivir
need
treat
peopl
immuneantiserum
show
inconsist
result
anim
studi
show
sera
often
fail
protect
lasv
challeng
anecdot
report
protect
human
convalesc
plasma
guinea
pig
high
neutral
titer
sera
impli
success
combin
ribavirin
plu
immun
serum
increas
surviv
lasvinfect
monkey
suggest
combin
might
use
treat
human
be
lf
combin
escherichia
coliexpress
human
plu
ribavirin
synergist
activ
slow
diseas
reduc
fatal
rate
hamster
inocul
arenaviru
serv
small
anim
model
lf
new
antivir
compound
lasv
develop
guinea
pig
treat
surviv
rate
contrast
surviv
among
control
ribavirintr
anim
anim
model
favipiravir
allow
full
recoveri
viru
picv
infect
sever
group
still
search
safe
effect
antilasv
medicin
exampl
zapata
et
al
publish
tabl
us
fdaapprov
drug
would
expect
counteract
diseaseassoci
geneexpress
chang
practic
biolog
obstacl
imped
search
lasv
vaccin
lasv
test
limit
facil
scarc
inconveni
genet
divers
among
lasv
strain
requir
vaccin
candid
induc
broad
crossprotect
immun
lack
knowledg
diseas
mechan
immun
correl
also
slow
progress
despit
obstacl
progress
made
earli
vaccin
studi
focus
inactiv
viru
elicit
strong
humor
immun
respons
fail
protect
rhesu
macaqu
lasv
challeng
protect
challeng
north
african
baboon
papio
hamadrya
differ
result
may
due
differ
nhp
model
inactiv
method
challeng
dose
viral
subparticl
peptid
lasv
np
confer
around
protect
mice
highli
toxic
sensit
mice
dna
vaccin
liveattenu
vector
promis
option
due
capac
induc
strong
cellular
immun
respons
one
oral
administr
recombin
aroaattenu
salmonella
typhimurium
express
lasvnp
induc
lasv
humor
cellmedi
immun
respons
mice
immun
vaccinia
viru
express
complet
glycoprotein
gene
gpc
np
lasv
partial
protect
guinea
pig
lasv
lethal
challeng
infect
anim
develop
viremia
lf
symptom
vaccinia
vector
express
sever
combin
lasv
structur
protein
np
success
nhp
use
construct
express
whole
gpc
combin
howev
immun
monkey
surviv
lf
challeng
still
infect
similar
result
seen
cynomolgu
macaqu
vaccin
vesicular
stomat
viru
vsv
express
lasvgpc
guinea
pig
vaccin
either
venezuelan
equin
enceph
yellow
fever
vector
express
lasvgpc
despit
achiev
protect
lethal
diseas
vector
often
trigger
small
increas
liver
enzym
detect
lasv
viremia
indic
partial
protect
vsvand
vacciniavector
lassa
vaccin
could
confer
protect
homolog
lasv
challeng
anim
model
safeti
concern
use
popul
high
hivseropreval
dampen
interest
exampl
vaccinia
vector
known
caus
pustul
infant
immunesuppress
peopl
wherea
vsv
vector
neurotrop
caus
enceph
live
vector
confin
vaccin
person
pose
danger
bystand
weak
immun
system
mopeia
viru
mopv
close
relat
lasv
infect
mastomi
speci
rodent
lasv
mopv
endem
area
report
lassalik
case
anim
inocul
viru
surviv
lasv
lethal
challeng
observ
suggest
mopv
may
excel
natur
vaccin
fear
mopv
genom
could
reassoci
virus
transform
human
pathogen
mitig
fact
attenu
form
virus
much
abund
fulli
immun
popul
laboratori
develop
character
reassort
viru
call
contain
l
segment
nonpathogen
mopv
segment
lasv
josiah
strain
l
segment
control
viru
replic
pathogenesi
segment
carri
viral
antigen
prove
vitro
vivo
attenu
parent
mopv
far
vaccin
provid
steril
immun
lethal
lasv
challeng
multipl
anim
model
use
broadli
differ
lasv
strain
lhf
vaccin
shown
elicit
strong
cellmedi
immun
respons
prior
challeng
allow
use
surrog
marker
efficaci
vaccin
product
guinea
pig
provid
effect
protect
deliv
day
challeng
postexposur
therapi
addit
safe
immunogen
rhesu
macaqu
aid
experi
add
valu
sinc
like
use
hiv
endem
area
lasv
postexposur
vaccin
profil
host
respons
emerg
technolog
predict
vaccin
efficaci
landmark
paper
respons
show
combin
six
upregul
gene
predict
good
antibodi
respons
man
none
six
biomark
upregul
vaccin
monkey
lassa
vaccin
candid
indic
marker
might
specif
yellow
fever
might
differ
human
nhp
transcriptom
profil
abl
demonstr
benign
natur
vaccin
even
context
aid
compar
lethal
infect
lcmvwe
sever
vaccin
candid
show
protect
lf
anim
model
howev
confer
steril
immun
broad
preand
postexposur
protect
advers
event
healthi
immunocompromis
anim
succeed
compli
twoanim
rule
requir
fda
comparison
vaccin
approach
produc
cheapli
west
africa
studi
vivo
vitro
sought
obtain
rnaexpress
profil
lasv
infect
profil
relat
arenaviru
lcmv
experi
aim
find
earli
diagnost
biomark
might
also
predict
diseas
outcom
virul
mild
infect
compar
order
identifi
chang
specif
sever
diseas
practic
reason
studi
concentr
venou
blood
sampl
viru
infect
primat
progress
previrem
virem
stage
recoveri
death
figur
rhesu
macaqu
infect
virul
lcmvwe
attenu
strain
lcmvarmstrong
lcmvarm
sampl
day
infect
euthan
human
blood
tissu
sampl
analyz
rna
extract
transcriptomeprofil
affymetrix
human
microarray
chip
probeset
repres
gene
differenti
regul
periper
blood
mononuclear
cell
pbmc
infect
virul
lcmvwe
mild
lcmvarmstrong
approxim
gene
differ
express
lcmvarm
lcmvwe
infect
gene
differenti
mild
sever
infect
previrem
stage
caveat
interpret
transcriptom
profil
chang
gene
express
alway
reflect
chang
gene
product
express
often
subject
posttranscript
control
therefor
present
profil
work
progress
previrem
gene
express
reveal
major
disrupt
eicosanoid
immun
respons
signal
pathway
eicosanoid
includ
prostaglandin
leukotrien
potent
arachidon
acid
deriv
activ
gene
downregul
virul
infect
disrupt
eicosanoid
pathway
could
contribut
myocard
hemorrhag
diseas
sign
immun
respons
gene
earli
growth
respons
gene
egr
egfr
downregul
earli
previrem
phase
ifnstimul
gene
isg
includ
oasl
upregul
remain
high
virem
phase
isg
upregul
viral
infect
tabl
known
antivir
function
like
promot
product
cytokin
innat
immun
earli
downregul
egfr
virul
lcmv
infect
nhp
similar
picvinfect
guinea
pig
model
shown
protein
phosphoryl
guinea
pig
infect
virul
attenu
isol
picv
attenu
viru
elicit
earli
proinflammatori
respons
suppress
host
cell
signal
increas
dna
bind
activ
dimer
wherea
increas
dna
bind
repress
homodimer
form
similar
mechan
report
suppress
express
cultur
cell
virul
attenu
arenavirus
metaanalys
profil
studi
sever
laboratori
identifi
transcript
factor
share
among
virul
infect
exampl
mitogenactiv
protein
kinas
pathway
particular
seem
control
respons
lcmv
infect
rna
profil
analys
liver
tissu
monkey
infect
lcmvwe
virul
lcmvarm
attenu
show
virus
alter
glucos
amino
acid
fatti
acid
metabol
addit
complement
coagul
cascad
main
group
affect
gene
includ
isg
innat
immun
respons
gene
eg
gene
also
upregul
sever
pathogen
virus
tabl
well
hepat
c
viru
hcv
trend
gene
express
may
similar
among
sever
viral
infect
signific
differ
seen
comparison
attenu
pathogen
virus
tabl
comparison
attenu
pathogen
arenavirus
differ
gene
express
reflect
differ
replic
potenti
virus
rather
fact
pathogen
virus
suppress
innat
immun
allow
higher
level
viru
product
high
viremia
trigger
inflammatori
respons
contribut
diseas
pathogen
nonpathogen
infect
upregul
isg
sinc
zapata
viremia
sustain
pathogen
viru
sustain
isg
express
becom
biomark
sever
diseas
treatment
would
includ
antivir
sinc
viral
compon
drive
isg
product
antiinflammatori
drug
nucleosid
reversetranscriptas
inhibitor
global
gene
express
use
predict
marker
diseas
outcom
transcriptom
analysi
rhesu
macaqu
liver
show
previou
transcriptom
analysi
blood
promin
express
inflammatoryrespons
gene
diseas
transcriptom
studi
viral
diseas
liver
also
identifi
higher
level
isg
common
theme
observ
signific
upregul
lcmvweinfect
liver
compar
nondiseas
liver
similar
increas
gene
express
seen
human
liver
infect
hcv
recent
paper
ebola
viru
transcriptom
note
cell
use
profil
actual
uninfect
bystand
respond
plasma
ifn
infect
cell
modul
antiifn
activ
viral
gene
larg
drop
hemoglobin
gene
express
virul
infect
attribut
ifn
inhibit
erythropoiesi
quit
possibl
primat
initi
platelet
dysfunct
treat
primat
diseas
platelet
transfus
done
murin
model
might
help
recoveri
exampl
earli
virusspecif
gene
express
serpin
gene
downregul
hcv
serpin
c
upregul
lcmv
liver
would
expect
inhibit
intrins
coagul
pathway
lcmvinfect
monkey
liver
signific
decreas
among
transcript
promot
glycogenolysi
eg
earli
stage
infect
increas
transcript
promot
gluconeogenesi
virem
previrem
stage
infect
like
gluconeogenesi
driven
hydrolysi
triglycerid
sinc
transcript
enzym
lipas
upregul
lcmvinfect
liver
geneexpress
chang
lcmv
infect
predict
glycolysi
plu
gluconeogenesi
constitut
futil
cycl
increas
usag
keton
bodi
fatti
acid
earli
follow
liver
function
glucoseproduc
role
use
fatti
acid
amino
acid
energi
sourc
alter
similar
respons
seen
fast
similar
observ
lcmv
viral
infect
also
affect
liver
energi
metabol
hbv
transcript
requir
regulatori
enzym
gluconeogenesi
encod
upregul
fast
cold
temperatur
stress
act
nuclear
receptor
forkhead
transcript
factor
glucocorticoid
receptor
remark
significantli
upregul
attenu
lcmv
infect
virul
infect
sendai
viru
transcript
initi
requir
tubulin
glycolyt
enzym
phosphoglycer
kinas
mayaro
alphaviru
increas
glucos
consumpt
infect
cell
may
directli
relat
viru
replic
phosphoglycer
kinas
key
glycolyt
enzym
glyceraldehyd
dehydrogenas
strongli
upregul
mild
pathogen
lcmv
infect
similarli
glyceraldehyd
dehydrogenas
need
life
cycl
zapata
salvato
page
futur
virol
author
manuscript
avail
pmc
januari
parainfluenza
viru
lcmvinfect
primat
express
decreas
express
moder
upregul
mrna
similar
situat
describ
hcv
infect
sever
lcmv
diseas
characterist
starvat
resembl
anorexia
appetit
loss
cachexia
wast
high
found
plasma
deceas
macaqu
lasv
infect
high
found
lcmvweinfect
macaqu
liver
stimul
protein
catabol
trigger
gluconeogenesi
anorexia
driven
mobil
fat
instead
protein
store
although
see
increas
saw
upregul
gene
protein
catabol
lipid
oxid
also
saw
earli
decreas
blood
triglycerid
corrobor
transcriptom
result
suppress
acetylcoacarboxylas
low
triglycerid
differenti
viral
diseas
bacteri
sepsi
high
triglycerid
coincid
high
liver
although
high
detect
day
high
circul
triglycerid
seen
day
death
lcmvweinfect
macaqu
metabol
chang
lcmvinfect
liver
may
account
lethal
diseas
resembl
lf
even
though
liver
transcriptom
resembl
starvat
possibl
due
appetit
loss
dehydr
primat
surviv
week
starvat
die
quickli
lasv
sinc
transcriptom
chang
affect
intermediari
metabol
seen
diseas
nondiseas
anim
unlik
chang
primari
caus
death
importantli
gene
involv
intermediari
metabol
consider
upregul
mild
compar
fatal
infect
lead
conclus
alter
energi
metabol
selfpreserv
mechan
pathogen
one
transcriptom
liver
lcmvwe
monkey
reveal
chang
gene
express
relat
fatti
acid
glucos
metabol
steroid
metabol
complement
coagul
cascad
mapk
signal
pathway
cell
adhes
virusinduc
cytokin
product
could
respons
platelet
dysfunct
diminish
erythropoiesi
alter
gene
express
relat
coagul
cascad
could
directli
respons
thrombocytopenia
capillari
leakag
sever
lcmv
infect
result
transcript
profil
cell
cultur
cautious
interpret
may
accur
reflect
take
place
live
tissu
liver
target
organ
lasv
one
studi
use
differenti
human
hepatoma
cell
line
transcriptom
profil
howev
studi
insignific
differ
seen
lasvor
lcmvinfect
cell
uninfect
control
anoth
transcriptom
studi
use
human
pbmc
expos
lasv
h
show
isg
compris
highli
affect
group
transcript
tabl
would
expect
rna
virus
instanc
influenzainfect
anim
yellow
fevervaccin
peopl
antivir
isg
common
group
upregul
gene
pbmc
mrna
isol
febril
episod
dengu
hf
exhibit
upregul
seen
lasvpbmc
exposur
lasv
infect
vivo
produc
high
level
viremia
mild
ifn
induct
insignific
tissu
damag
littl
macrophag
activ
vitro
lasv
effici
inhibitor
type
ifn
cytokin
product
contrast
less
virul
mopv
among
isg
encod
protein
tenfold
upregul
lasvexpos
pbmc
compar
cell
expos
vaccin
strain
encod
cytokin
belong
hematopoiet
ifninduc
nuclear
antigen
amino
acid
repeat
famili
gene
product
contain
domain
involv
dna
bind
transcript
regul
proteinprotein
interact
protein
local
nucleu
interact
inhibit
cell
growth
via
rasraf
signal
pathway
function
transcript
repressor
play
role
regul
hematopoiet
differenti
control
cellular
prolifer
ifitm
ifninduc
viral
restrict
factor
differenti
restrict
cellular
entri
envelop
virus
influenza
flavi
filovirus
modul
cellular
tropism
independ
viral
receptor
express
even
though
envelop
rna
virus
share
entri
mechan
arenavirus
pseudoparticl
express
envelop
glycoprotein
lcmv
lasv
macv
well
mlv
retroviru
restrict
ifitm
express
vaccin
strain
downregul
gene
relat
ifn
pathway
includ
inhba
neg
regul
tr
ail
rige
gene
well
immun
responserel
gene
itgam
encod
integrin
viperin
express
lasv
interstiti
collagenas
upregul
lasv
versu
expos
cell
mmp
protein
involv
normal
breakdown
extracellular
matrix
reproduct
tissu
remodel
embryon
develop
also
involv
metastasi
arthriti
interact
hiv
transactiv
protein
tat
result
degrad
tat
downregul
tatmedi
transactiv
neurotox
sever
cytokin
antiinflammatori
activ
upregul
expos
pbmc
lasv
cytokin
inhibin
inhba
subunit
join
subunit
form
pituitari
folliclestimul
hormon
secret
inhibitor
inhibin
neg
regul
gonad
stromal
cell
prolifer
tumorsuppressor
activ
vaccinia
virusinduc
inhba
express
mediat
viral
protein
block
express
multipl
cytokin
antagon
signal
cascad
gene
also
upregul
pbmc
expos
lasv
share
function
homolog
clinic
studi
show
serum
level
higher
patient
nonfat
lf
along
proinflammatori
chemokin
lower
patient
fatal
lf
clinic
data
match
result
observ
primari
human
cell
vitro
anim
model
fatal
lf
also
seem
higher
level
protect
lf
vivo
cell
cultur
studi
show
replic
lasv
monocytederiv
mp
dc
associ
suppress
innat
immun
respons
vivo
studi
patient
experiment
anim
show
cytokin
possibl
come
uninfect
bystand
cell
recruit
immun
cell
increas
surviv
view
contrast
earli
cytokin
storm
observ
filoviru
hf
contrast
hf
caus
south
american
arenavirus
machupo
junin
hemorrhag
dissemin
intravascular
coagul
rare
seen
patient
lf
nevertheless
lasv
effect
vascular
function
coagul
abnorm
involv
lf
pathogenesi
platelet
remain
either
normal
moder
low
strong
reduct
platelet
function
plasma
lhf
patient
inhibitori
activ
platelet
healthi
individu
suggest
presenc
solubl
factor
caus
platelet
malfunct
show
vitro
replic
lasv
endotheli
cell
huvec
produc
high
viru
titer
plaqueform
unit
pfu
ml
without
caus
cpe
howev
cellular
function
perturb
includ
reduc
level
infect
huvec
nonpathogen
mopv
effect
product
suggest
lhf
diseas
may
direct
consequ
cpe
like
due
alter
express
solubl
factor
dampen
immun
six
gene
relat
coagul
pathway
differ
express
lasvexpos
versu
pbmc
thrombomodulin
thbd
hbegf
itgam
plau
pdecgf
thbd
predominantli
synthes
vascular
endotheli
cell
kda
type
transmembran
protein
form
molar
complex
thrombin
exert
pronounc
inhibitori
effect
thrombot
inflammatori
redoxrel
respons
initi
respons
thrombin
gener
thbd
significantli
enhanc
rate
thrombin
inactiv
atiii
dramat
acceler
abil
thrombin
activ
protein
c
valid
cdna
array
result
dc
deriv
human
pbmc
expos
lasv
versu
thbd
express
measur
elisa
level
secret
thbd
cultur
cell
expos
lasv
differ
correl
transcriptom
data
exposur
lasv
upregul
thbd
secret
exposur
opposit
effect
treat
lp
result
lower
level
secret
thbd
includ
lasvexpos
cell
presenc
thrombin
thbd
gener
activ
protein
c
apc
inhibit
proinflammatori
procoagul
respons
factor
v
activ
fibrinogen
cleavag
platelet
activ
upregul
leukocyt
adhes
molecul
chemotaxi
neutrophil
monocyt
treat
cell
shorten
halflif
thbd
mrna
hypothesi
higher
thbd
apc
lower
ifn
respons
respons
absenc
inflammatori
cell
infiltr
hemorrhag
symptom
seen
lf
current
view
massiv
lasv
infect
endotheli
antigenpres
cell
would
increas
express
membran
solubl
thbd
form
activ
apc
captur
antiinflammatori
anticoagul
effect
given
result
inhibit
thbd
could
therapeut
strategi
experiment
lf
primat
upregul
coagulationrel
gene
might
also
contribut
lf
diseas
exampl
includ
plau
anticlot
effect
hbegf
involv
blood
vessel
kidney
patholog
promot
vascular
matur
conjunct
pdecgf
tymp
platelet
marker
upregul
cell
expos
lasv
h
highaffin
lasv
bind
cellular
receptor
perturb
signal
interact
integrin
dystroglycan
thu
zapata
futur
virol
author
manuscript
avail
pmc
januari
inhibit
mekerk
signal
receptor
ubiquit
extracellular
matrix
ecm
protein
cooper
integrin
control
cellmatrix
interact
thu
virusinduc
perturb
may
contribut
function
chang
among
epitheli
vascular
endotheli
cell
contribut
shock
death
lf
patient
also
know
arenavirus
bind
directli
platelet
inhibit
function
mechan
would
exacerb
high
viremia
trigger
upregul
itgam
pdecgf
arteri
injuri
leukocyt
recruit
increas
itgam
express
allow
fibrinogen
platelet
bind
vessel
wall
lasvinduct
itgam
pdecgftymp
increas
platelet
sequestr
tissu
decreas
number
circul
platelet
hemorrhag
episod
differenti
express
gene
may
contribut
pathogen
phenotyp
lasv
attenu
behavior
vaccin
strain
primat
infect
lasv
dc
initi
cellular
target
kupffer
cell
hepatocyt
adren
cortic
cell
endotheli
cell
infect
later
stage
termin
diseas
pbmc
cultur
expos
lasv
signific
transcriptom
differ
observ
h
exposur
even
though
mononuclear
cell
pbmc
cultur
permiss
lasv
sinc
viru
replic
differenti
monocyt
mp
dc
repres
approxim
circul
pbmc
permiss
viru
replic
thu
geneexpress
profil
lasvor
pbmc
primarili
gene
express
uninfect
bystand
cell
receiv
signal
contact
viru
particl
infect
dc
dcproduc
cytokin
ifn
product
infect
cell
inhibit
interact
viral
np
interact
z
protein
complex
affect
pathway
favor
suppress
chemokin
type
ifn
sinc
virul
nonvirul
virus
capac
inhibit
pathway
primarili
viru
replic
level
determin
effect
vivo
byproduct
viru
replic
noninfecti
viru
particl
may
still
trigger
uninfect
bystand
cell
express
isg
upregul
isg
observ
pbmc
transcriptom
studi
particl
might
drive
gene
express
virem
stage
vivo
lasv
ident
envelop
protein
capabl
bind
differ
lasv
due
substitut
locat
fusion
domain
rrll
motif
cleavag
site
cellular
subtilas
substitut
lysin
k
glutam
acid
e
introduc
two
neg
charg
r
group
posit
aspglu
distinguish
lasv
glycoprotein
analyz
far
potenti
affect
fusion
contribut
postfus
event
well
attenu
final
expos
human
pbmc
virus
mimic
virem
stage
infect
expos
pbmc
lasv
vaccin
strain
show
lasv
affect
gene
involv
coagul
pathway
exampl
lasv
exposur
strongli
upregul
mrna
protein
express
thbd
suggest
connect
inflammatori
vascular
abnorm
lead
death
latestag
lf
patient
base
current
knowledg
thbd
involv
procoagul
proinflammatori
pathway
thbd
inhibit
could
promis
target
therapeut
intervent
lf
anim
model
studi
lasvinfect
cynomolgu
macaqu
compar
surviv
nonsurviv
anim
fatal
case
suffer
fever
weight
loss
high
viremia
acut
respiratori
distress
wherea
survivor
lower
viral
load
fewer
diseas
sign
anim
develop
strong
antibodi
respons
survivor
develop
earlier
similarli
type
ifn
detect
soon
infect
survivor
termin
stage
nonsurvivor
infect
monkey
upregul
chemokin
gene
itac
peripher
blood
mononuclear
cell
lymph
unlik
peopl
surviv
lf
macaqu
survivor
lower
level
note
previous
lcmvweinfect
rhesu
macaqu
high
level
plasma
detect
fatal
survivor
high
count
activatedmonocyt
rise
number
circul
monocyt
contrast
low
circul
monocyt
activ
prolifer
cell
fatal
case
earli
strong
immun
respons
need
control
viru
replic
associ
recoveri
fatal
infect
character
weak
immun
respons
uncontrol
viral
replic
investig
surpris
macaqu
given
high
dose
pfu
lasv
like
surviv
given
low
dose
pfu
lasv
result
howev
consist
view
higher
dose
would
increas
signal
respons
uninfect
bystand
cell
pois
anim
resist
fatal
diseas
bystand
cell
secret
inflammatori
cytokin
attract
immunesurveil
site
infect
promot
robust
antivir
immun
phenomenon
yield
previremia
transcriptom
profil
similar
found
virem
phase
seen
vitro
pbmc
expos
lasv
similar
phenomenon
work
attenu
lasv
vaccin
deliv
therapeut
lethal
challeng
profil
lasvinfect
cynomolgu
macaqu
compar
profil
lasv
expos
pbmc
figur
profil
lcmvinfect
rhesu
macaqu
figur
figur
blue
circl
repres
differenti
regul
gene
lasvinfect
macaqu
virem
phase
base
ingenu
pathway
analysi
gene
highli
interconnect
figur
gene
symbol
correspond
upregul
gene
lasvexpos
pbmc
circl
red
common
gene
downregul
circl
black
two
import
node
repres
gene
whose
product
interact
mani
isg
product
proinflammatori
molecul
notabl
gene
product
upregul
equal
well
virul
lasv
nonvirul
studi
virusexpos
pbmc
gene
express
chemokin
mark
star
upregul
much
lasv
studi
also
outstand
studi
human
lf
survivor
studi
macaqu
lf
survivor
import
attract
immunosurveil
infect
site
zapata
futur
virol
author
manuscript
avail
pmc
januari
uniqu
featur
lasvmacaqu
studi
sever
neutrophilspecif
gene
upregul
center
node
elan
elastas
neutrophil
note
pbmc
usual
contain
neutrophil
remov
purif
rna
extract
cell
includ
amongst
pbmc
patholog
lasvinfect
cynomolgu
macaqu
associ
increas
band
immatur
neutrophil
conner
jh
per
comm
downregul
nuclear
receptor
circl
black
figur
encod
transcript
factor
induc
antiinflammatori
gene
product
notabl
downregul
lasvexpos
pbmc
well
lcmvweinfect
rhesu
macaqu
major
biomark
differenti
pathogen
nonpathogen
infect
also
downregul
group
lasvmacaqu
studi
accord
latest
public
see
figur
although
downregul
earli
previrem
stage
lcmv
macaqu
still
need
valid
predict
biomark
viral
hemorrhag
fever
vhf
express
gene
lcmvweinfect
rhesu
macaqu
strong
agreement
dataset
except
gene
neutrophil
cluster
discord
gene
lcmvwe
model
either
downregul
bare
affect
eg
hemoglobin
hba
hbb
hbd
ltf
rora
gene
impact
eicosanoid
pathway
contribut
edema
myocard
number
lf
diseas
sign
although
tantal
specul
role
gene
hf
experiment
studi
still
need
document
protein
chang
confirm
effect
lasv
pathogenesi
initi
studi
nhp
continu
expand
previrem
biomark
diseas
determin
predict
develop
pathogen
nonpathogen
infect
lhf
survivor
control
viral
load
earli
infect
fatal
case
poor
inflammatori
respons
character
lymphopenia
lymphocyt
subset
b
nk
cell
along
necrosi
lymphoid
organ
immunosuppress
state
establish
earli
viru
exposur
vitro
infect
mp
dc
endotheli
cell
downregul
product
inflammatori
mediat
key
mechan
immun
suppress
rna
virus
activ
dc
mp
produc
dsrna
genom
intermedi
recogn
pattern
recognit
molecul
activ
follow
ifn
respons
induc
cellular
gene
involv
innat
adapt
immun
respons
inhibit
viru
replic
although
sensit
antivir
effect
strain
lasv
differ
control
ifn
product
vitro
vivo
lethal
infect
anim
level
moder
elev
human
fatal
case
level
increas
individu
monkey
ifn
type
detect
earli
survivor
termin
stage
fatal
diseas
inhibit
ifn
lasv
affect
pdc
matur
dc
product
cytokin
chemokin
viral
nucleoprotein
np
play
import
role
ifn
control
prevent
activ
plu
nuclear
transloc
ifn
type
activ
downstream
induct
isg
antiifn
function
locat
within
np
cterminu
function
structur
studi
show
homolog
region
deddh
famili
exoribonucleas
crystal
structur
interact
rigi
suggest
np
ribonucleas
activ
remov
viral
pamp
rna
therebi
avoid
recognit
patternrecognit
receptor
inhibit
ifn
product
report
lasv
infect
monocyt
endotheli
cell
cultur
suppress
induct
effect
would
expect
inhibit
inflamm
neutrophil
migrat
subsequ
two
lasvresearch
group
one
lyon
one
atlanta
ga
usa
corrobor
idea
virul
viru
suppress
express
chemokin
could
stimul
acquir
immun
howev
minor
disagr
result
one
group
dc
incub
infecti
inactiv
lasv
produc
littl
group
dc
mp
incub
infecti
lasv
suppress
inactiv
viru
particl
foster
product
chemokin
lyon
group
conclud
lasv
stock
atlanta
group
probabl
contain
signific
quantiti
noninfecti
viral
product
impli
replic
infecti
particl
need
suppress
innat
immun
find
later
corrobor
other
two
find
human
be
lf
lent
weight
idea
innat
immun
suppress
sever
infect
first
fatal
case
lhf
lower
chemokin
level
compar
survivor
second
cytokin
peak
infect
contact
sever
lasv
case
develop
lf
diseas
addit
studi
primat
human
pbmc
expos
viru
succeed
link
virul
infect
undetect
level
low
level
plasma
inhibit
mrna
express
appear
high
level
plasma
lhf
fatal
case
monkey
infect
lcmvwe
high
level
last
stage
sever
lf
could
result
hepat
regener
may
associ
neutrophilia
anoth
function
appear
decreas
lasvinfect
dc
matur
marker
capac
migrat
secondari
lymphoid
organ
mechan
diseas
involv
lasv
target
monocyt
dc
inhibit
initi
immun
respons
suppress
migrat
activ
cell
primari
site
infect
viral
effect
host
gene
express
result
immun
suppress
higher
viral
replic
increas
virul
treat
human
anim
immun
serum
show
variou
result
promis
discourag
neutral
antibodi
might
role
lasv
protect
especi
high
titer
achiev
natur
infect
naiv
host
enough
time
mount
protect
antibodi
respons
howev
clinic
serolog
studi
need
defin
role
neutral
antibodi
lhf
recoveri
reinfect
recov
acut
lf
patient
overcom
initi
lymphopenia
develop
strong
immun
respons
np
respons
partial
strainspecif
crossreact
among
lasv
strain
respons
recogn
conserv
epitop
common
old
world
similar
lcmv
new
world
arenavirus
similar
immun
monkey
guinea
pig
lcmv
mobv
mopv
nonpathogen
old
world
virus
confer
protect
lf
diseas
anim
tcell
respons
import
bcell
respons
ctlmediat
protect
reli
cell
cell
howev
mechan
protect
remain
unknown
studi
need
human
case
infect
character
role
cell
lhf
protect
lasvinfect
monkey
tcell
activ
delay
fatal
case
vitro
lymphoprolif
respons
appear
decreas
b
cell
downregul
class
ii
mhc
antigen
also
seen
contrast
fatal
case
survivor
show
tcell
activ
prolifer
exposur
inactiv
lasv
particl
also
increas
circul
monocyt
similarli
immun
marmoset
increas
cell
popul
lasv
challeng
conclus
much
evid
suggest
inhibit
patternrecognit
receptor
lasv
earli
infect
failur
induc
proinflammatori
cytokin
result
immunosuppress
uncontrol
viru
replic
late
vhf
diseas
sever
differ
viral
infect
character
high
inflammatori
respons
eg
inflammasom
produc
high
thu
earli
strong
immun
respons
control
viru
replic
like
promot
recoveri
lhf
diseas
inflammasom
inhibitor
would
reason
treatment
late
diseas
futur
effort
lassa
research
depend
improv
diagnost
technolog
monitor
vaccin
evalu
vaccin
candid
valid
therapi
base
modul
host
respons
much
conting
previrem
biomark
lassa
infect
incorpor
diagnost
confirm
infect
statu
clearli
defin
diseas
stage
rapid
analysi
geneexpress
pattern
may
use
directli
studi
order
identifi
best
protect
biomark
develop
test
antivir
therapi
drug
proceed
anim
model
human
clinic
trial
transcriptom
profil
studi
alreadi
point
new
therapeut
target
eg
downregul
eicosonoid
pathway
could
counteract
prostacyclin
bryostatin
sever
fdaapprov
drug
predict
treat
vhf
suggest
cell
cultur
studi
direct
effect
infecti
noninfecti
viru
particl
pbmc
show
lasv
upregul
thbd
interfer
coagul
inhibitor
thbd
defin
anoth
class
potenti
therapi
besid
develop
sensit
earli
diagnost
prevent
public
health
educ
vaccin
research
high
prioriti
biomark
valid
use
vaccin
studi
studi
lassa
vaccin
candid
rhesu
macaqu
model
aid
studi
character
geneexpress
chang
usual
associ
benign
infect
indic
vaccin
attenu
even
immunosuppress
anim
mani
benefit
attenu
lasv
vaccin
candid
receiv
insuffici
attent
far
advanc
clinic
trial
forti
year
lhf
diseas
describ
molecular
biolog
lasv
well
known
lack
tool
need
achiev
seriou
reduct
preval
sever
lassa
hf
rapid
diagnost
effect
vaccin
clear
understand
lasv
pathogenesi
need
advanc
develop
therapeut
molecular
diagnost
led
geneexpress
profil
offer
solid
contribut
improv
understand
lf
contribut
prevent
treatment
diseas
histori
lassa
emerg
west
africa
endem
area
west
africa
seropreval
fatal
clinic
manifest
sever
diseas
present
myocard
edema
respiratori
distress
elev
astalt
viremia
high
plasma
enceph
vascular
leakag
hear
loss
third
hospit
case
lassa
viru
infect
anim
model
diseas
sign
resembl
human
lassa
fever
lf
rhesu
cynomolgu
macaqu
less
marmoset
guinea
pig
diseas
mice
dissimilar
human
lf
requir
high
dose
strongli
mmunopathogen
diagnosi
diagnost
design
detect
host
respons
viremia
current
diagnost
detect
viral
antigen
antivir
immun
respons
viru
isol
gold
standard
diagnosi
infect
primat
previrem
stage
virem
stage
final
stage
recoveri
morbid
blood
transcriptom
reveal
least
previrem
gene
discrimin
virul
benign
infect
chang
lymphocyt
choriomening
viru
strain
lcmvwe
blood
transcriptom
show
major
disrupt
eicosnoid
immun
respons
signal
pathway
diseas
sign
fatigu
hemorrhag
coagul
defect
myocard
could
relat
chang
seen
blood
liver
transcriptom
previrem
stage
biomark
diseas
enabl
predict
possibl
treatment
metaanalysi
guinea
pig
result
reveal
similar
transcript
factor
control
viral
hemorrhag
fever
differ
anim
model
liver
transcriptom
lcmvwe
monkey
reveal
impact
fatti
acid
glucos
metabol
steroid
metabol
complement
coagul
cascad
mapk
signal
pathway
cell
adhes
human
cynomolgu
macaqu
survivor
lf
higher
cxc
chemokin
profil
lasvexpos
human
cell
transcriptom
profil
human
periper
blood
mononuclear
cell
expos
lasv
model
virem
stage
vivo
infect
profil
domin
ifnsensit
gene
common
antivir
pattern
even
respons
inactiv
viru
particl
noninfect
cell
direct
effect
viral
gene
viru
particl
demonstr
cell
cultur
transcriptom
profil
vivo
indirect
effect
viru
uninfect
bystand
cell
exposur
periper
blood
mononuclear
cell
lasv
vaccin
strain
show
lasv
affect
gene
involv
coagul
pathway
profil
lasvinfect
nonhuman
primat
studi
lyon
show
cynomolgu
macaqu
infect
high
dose
lasv
surviv
frequent
given
low
dose
propos
high
dose
insur
earli
effect
innat
immun
ft
detrick
studi
compar
lasv
infect
infect
nonpathogen
viru
see
upregul
gene
upregul
respons
viral
infect
ft
detrick
studi
distinct
lcmvwe
model
lasv
infect
neutrophil
marker
upregul
nonhuman
primat
studi
continu
order
valid
previrem
marker
test
therapi
immunosuppress
state
establish
earli
lasv
exposur
character
poor
inflammatori
respons
lead
uncontrol
viru
replic
surviv
individu
show
earli
increas
ifn
level
lethal
case
show
ifn
termin
stage
lethallyinfect
anim
ifnlevel
moder
elev
human
fatal
case
ifnlevel
increas
individu
high
serum
document
lassa
case
lcmvwe
monkey
explain
lasv
infect
hepatocyt
monocytederiv
macrophag
lasv
suppress
product
therefor
must
bystand
sourc
geneexpress
profil
expand
knowledg
lassa
hemorrhag
fever
diseas
well
improv
diagnosi
treatment
option
ingenu
pathway
analysi
softwar
use
analyz
list
gene
upregul
pbmc
lassa
challeng
cynomolgu
macaqu
node
repres
gene
symbol
product
particip
proteinprotein
interact
straight
line
repres
simpl
interact
arrow
repres
control
one
gene
product
anoth
loop
repres
selfregul
gene
encircl
red
also
note
express
lasvexpos
human
pbmc
encircl
black
gene
downregul
lymphocyt
choriomening
viru
strain
monkey
model
notabl
gene
product
connect
node
similarli
upregul
pbmc
expos
either
virul
lasv
nonvirul
note
express
exposur
exposur
lasv
evid
survivor
succumb
lassa
fever
lasv
lassa
viru
nhp
nonhuman
primat
pbmc
periper
blood
mononuclear
cell
adapt
permiss
figur
zapata
futur
virol
author
manuscript
avail
pmc
januari
ingenu
pathway
analysi
softwar
use
analyz
list
gene
upregul
periper
blood
mononuclear
cell
lassa
challeng
cynomolgu
macaqu
blue
circl
contain
symbol
gene
name
product
particip
proteinprotein
interact
straight
line
repres
simpl
interact
arrow
repres
control
one
gene
product
anoth
loop
repres
selfregul
gene
encircl
red
also
note
express
lcmvweinfect
nonhuman
primat
notabl
gene
product
connect
node
similarli
upregul
periper
blood
mononuclear
cell
expos
either
virul
lcmvwe
nonvirul
lcmvarm
lcmvweinfect
nhp
effect
seen
elan
strong
downregul
encircl
black
seen
mild
insignific
downregul
hemoglobin
hba
hbb
hbd
ltf
rora
observ
gene
upregul
exposur
differ
rna
dna
virus
name
commonli
upregul
gene
cell
expos
viru
gene
ifnstimul
gene
isg
virus
lasv
vaccin
strain
yellow
dengu
viru
hantaviru
ebola
viru
vaccin
strain
poxviru
vaccinia
lasv
lassa
viru
